scholarly journals Epidemiology of Leprosy in Vietnam and the Effectiveness of Multidrug Therapy (MDT) in the Management of the Disease

2019 ◽  
Author(s):  
Tran Hau Khang ◽  
Ngo Minh Thao ◽  
Le Huu Doanh
Keyword(s):  
Multidrug Therapy

scholarly journals HIV-1 mutational pathways under multidrug therapy

2011 ◽  
Vol 8 (1) ◽  
pp. 26 ◽  
Author(s):  
Glenn Lawyer ◽  
André Altmann ◽  
Alexander Thielen ◽  
Maurizio Zazzi ◽  
Anders Sönnerborg ◽  
...  
Keyword(s):  
Multidrug Therapy ◽  
Hiv 1

Type I reaction in a borderline leprosy case successfully treated with multidrug therapy and ofloxacin

2008 ◽  
Vol 47 (10) ◽  
pp. 1084-1086
Author(s):  
Daniel Asz-Sigall ◽  
Lirio López-García ◽  
Yvette Neme-Yunes ◽  
Ricardo Yuen-Palos ◽  
Maria Elisa Vega-Memije ◽  
...  
Keyword(s):  
Type I ◽  
Multidrug Therapy ◽  
Leprosy Case

S275 – Nasal Morphology and Nasal Patency in Leprosy Patients

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P167-P167
Author(s):  
Maria Teresa Torres Larrosa ◽  
Luis Jorge Peréz Peréz ◽  
Juan-Jose Artazkoz-del Toro
Keyword(s):  
Drug Therapy ◽  
Therapy Group ◽  
Control Group ◽  
Nasal Patency ◽  
Multidrug Therapy ◽  
Airway Patency ◽  
Expiratory Resistance ◽  
Leprosy Patients ◽  
The Right ◽  
The Impact

Objectives 1) To assess the impact of multi-drug leprosy therapy on the development of nasal deformities and nasal airway patency. 2) Evaluate the nasal morphology and nasal patency in leprosy patients treated with the multidrug therapy in comparison with patients treated with 1 drug therapy and a group of healthy volunteers. Methods In an overall group of 84 patients studied, 38 were treated with a therapy based on a single drug, and 22 were treated with multi-drug therapy, while 24 subjects formed a control group. We used anterior rhinoscopy to analised the morphology of the nose. We meassured the nasal inspiratory and expiratory resistance of the right and left nostrils and total nasal inspiratory and expiratory resistance at a transnasal pressure of 150 Pa. by using active anterior rhinomanometry. The statistical analysis was carried out using the Varianza analisys. Results The nasal structures in the 1-drug therapy group underwent bone and cartilaginous resorption with an increase in nasal resistances. We found significant statistical differences between the resistance values obtained in this group and the control group (p<0,05). In the multidrug therapy group, the morphology of the nose remains as in healthy patients. No significant statistical differences were found between the resistance values obtained in the multidrug therapy patients and the control group (P>0,05). Conclusions The multidrug therapy prevents developing nasal deformities and maintains a normal nasal airflow.

Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance

2021 ◽  
Vol 21 ◽  
Author(s):  
Harish C. Upadhyay
Keyword(s):  
Drug Resistance ◽  
Antimicrobial Agents ◽  
Plant Secondary Metabolites ◽  
Cost Effective ◽  
Resistance Mechanisms ◽  
Biologically Active ◽  
Multidrug Therapy ◽  
Diverse Range ◽  
Development Of Resistance ◽  
Hybrid Molecules

: No doubt antibiotics have saved billions of lives, but lack of novel antibiotics, development of resistance mechanisms in almost all clinical isolates of bacteria, and recurrent infections caused by persistent bacteria hamper the successful treatment of infections. Due to widespread emergence of resistance, even the new families of antimicrobial agents have a short life expectancy. Drugs acting on single target often lead to drug resistance and are associated with various side effects. To overcome this problem either multidrug therapy or single drug acting on multiple targets may be used. The later are called ‘hybrid molecules’ which are formed by clubbing two biologically active pharmacophores together with or without an appropriate linker. In this rapidly evolving era, the development of natural product-based hybrid molecules may be a super-alternative to multidrug therapy to combat drug resistance caused by various bacterial and fungal strains. Coumarins (benzopyran-2-one) are one of the earliest reported plant secondary metabolites having clinically proven diverse range of pharmacological properties. On the other hand, 1,2,3-triazole is a common pharmacophore in many drugs responsible for polar interactions improving the solubility and binding affinity to biomolecular targets. In this review we discuss recent advances in Coumarin-1,2,3-triazole hybrids as potential antibacterial agents aiming to provide a useful platform for the exploration of new leads with broader spectrum, more effectiveness, less toxicity with multiple modes of action for the development of cost-effective and safer drugs in the future.

scholarly journals Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

2011 ◽  
Vol 3 ◽  
pp. CMT.S6565
Author(s):  
Yasushi Saito
Keyword(s):  
Cardiovascular Events ◽  
Treatment Options ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Multidrug Therapy ◽  
Low Density Lipoprotein Cholesterol ◽  
Coronary Syndrome ◽  
Sustained Action ◽  
Plaque Regression

Pitavastatin is one of the most effective treatment agents for lowering serum low-density lipoprotein cholesterol (LDL-C) levels. Because pitavastatin is scarcely metabolized, the risk of drug-drug interactions during multidrug therapy is low, and the LDL-C target is achieved in the majority of patients. The incidence of adverse events associated with pitavastatin treatment has so far been comparable to or lower than that associated with other statins, and glucose metabolism is not affected by the drug. Pitavastatin promotes plaque regression and improves the plaque composition in patients with acute coronary syndrome. The serum level of high-density lipoprotein cholesterol (HDL-C) during treatment with pitavastatin was demonstrated to be inversely associated with the incidence of cardiovascular events. Because of its effective and sustained action to increase HDL-C, pitavastatin is expected to contribute to the prevention of cardiovascular events, in addition to its potent LDL-C lowering effect, especially in patients with low serum HDL-C levels.

scholarly journals Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19)

2021 ◽  
Author(s):  
Brian Procter ◽  
Casey Ross ◽  
Vaness Pickard ◽  
Erica Smith ◽  
Cortney Hanson ◽  
...  
Keyword(s):  
High Risk ◽  
Volume Expansion ◽  
Cleveland Clinic ◽  
Multidrug Therapy ◽  
Cumulative Mortality ◽  
High Risk Patients ◽  
Ambulatory Treatment ◽  
Period 2 ◽  
Risk Patients ◽  
Inhaled Budesonide

Background. There is an emergency need for early ambulatory treatment of COVID-19 in acutely ill patients in an attempt to reduce disease progression and the risks of hospitalization and death. Methods and Results. We recently reported results on 320 high-risk (age > 50 with ≥ 1 comorbidity) COVID-19 cases and have updated our results with 549 additional cases in period ending December 16, 2020. Our protocol utilizes at least two agents with antiviral activity against SARS-CoV-2 (zinc, hydroxychloroquine, ivermectin) and one antibiotic (azithromycin, doxycycline, ceftriaxone) along with inhaled budesonide and/or intramuscular dexamethasone. Albuterol nebulizer, inhaled budesonide, intravenous volume expansion with supplemental parenteral thiamine 500 mg, magnesium sulfate 4 grams, folic acid 1 gram, vitamin B12 1 mg, are administered for severely ill patients who either present or return to the clinic with severe symptoms. In period 1 (April-September, 2020) 6/320 (1.9%) and 1/320 (0.3%) patients that were hospitalized and died, respectively. In period 2, (September-December, 2020) 14/549 (2.6%) and 1/549 (0.18%) were hospitalized and died, respectively. For comparison, we used the Cleveland Clinic COVID-19 hospitalization calculator and based on average age and comorbidities the expected rate of hospitalization for both periods was 18.5%. The cumulative mortality among confirmed and suspected COVID-19 in Collin, Dallas, Denton, and Tarrant counties was 0.76, 1.04, 0.90, and 0.97. As a result, our early ambulatory treatment regimen was associated with estimated 87.6% and 74.9% reductions in hospitalization and death respectively, p<0.0001. Conclusions. We conclude that early ambulatory, multidrug therapy is associated with substantial reductions in hospitalization and death compared to available rates in the community. Prompt ambulatory treatment should be offered to high-risk patients with COVID-19 instead of watchful watching and late-stage hospitalization for salvage therapies.

Sign in / Sign up

Export Citation Format

Share Document